Nigerian Journal of Pharmaceutical and Applied Science Research,
Vol.14 (4): 35-44; Decemberr 2025 *ISSN: 2971-737X (Print); ISSN: 2971-7388.*
Available at www.nijophasr.net https://doi.org/10.60787/nijophasr-v14-i4-637

Antispasmodic and Toxicological effects of methanol extract of *Chromolaena odorata* on jejunum muscle in animal models

[1]Armstrong C. Ukah, [1*]Adedayo A. Tologbonse, [1]Nkechi J. Onyeukwu, [2]Ngozi, A. Onwuka [3]Archibong A. Michael, [1] Herbert O.C. Mbagwu, [1]Mmaduabuchi N. Omeluko, [1]Ejika I. Abam, [1] Titilayo E. Tologbonse, [1]Susana A. Attah, [1] Chukwuemelie G. Elochukwu and [1]Hillary E. Otimanam

[1] Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Uyo, Uyo, Nigeria.
[2]Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, Rivers State University, Port Harcourt, Nigeria.
[3] Department of Medical Laboratory Services (Histopathology), University of Uyo Teaching Hospital, Uyo, Nigeria

Article info: Volume 14, Issue 4, December 2025; Received: 1 December 2025; Reviewed: 29 December 2025; Accepted: 29 December 2025; Published: 15 January 2026; *DOI: 10.60787/nijophasr-v14-i4-637*

ABSTRACT

Background: *Chromolaena odorata*, widely used in traditional medicine for diabetes, malaria, wounds, gastrointestinal disorders and inflammation, was evaluated for its in vitro effects on jejunal smooth muscle contractility and relaxation, as well as its histological toxicity, using methanol extracts in animal models.

Methods: Acute toxicity was assessed using modified Lorke's method in thirty adult mice (20–30 g) randomized into six groups. In vitro studies were conducted using twenty matured Wistar rats (180–200 g) divided into four groups of five animals each. Jejunum muscle strips were mounted in an organ bath containing Tyrode's solution for contractility assessment. Histological evaluation of harvested jejunum tissues was performed using Mayer's haematoxylin and eosin staining techniques.

Results: The median lethal dose (LD_{50}) of the extract was 2738.61 mg/kg, indicating relatively low acute toxicity. The extract produced dose-dependent antispasmodic effects on jejunal smooth muscle, mediated partly via muscarinic receptors, as demonstrated by atropine antagonism. At 2×10^{-2} mg/ml, the extract elicited the maximum relaxation response (-7.0 ± 0.58 mm; 100% of maximal response), although it was less potent than atropine and not statistically significant at $P < 0.05$. Histological findings showed that low doses were safe, whereas higher doses induced moderate mucosal damage.

Conclusion: The methanol extract of C. odorata exhibits dose-dependent antispasmodic activity on jejunal smooth muscle, primarily through muscarinic receptor pathways. Low doses appear safe, while higher doses require caution. These findings may validate its traditional use in gastrointestinal disorders and highlight its potential as a natural antispasmodic agent.

Keywords: antispasmodic; *Chromolaena odorata*; jejunum; methanol and toxicity.

1. INTRODUCTION

Chromolaena odorata (Asteraceae) also known as *Chromolaena odorata (L)* King commonly known as Siam weed, is a fast-growing perennial and invasive weed native to South and Central America. It has been introduced into the tropical regions of Asia, Africa and other parts of the world. *C. odorata* is also known by various other names such as Armstrong's Weed, Baby Tea, Jack in the bush, King Weed, Paraffin Bush, Paraffin Weed Bitter Bush, Butterfly Weed, Christmas Bush, Devil Weed, Eupatorium, Turpentine Weed and Triffid Weed [1]. C*hromolaena odorata* L. has a short life cycle of approximately ten years. It occasionally reaches its maximum height of 6 m as a climber on other vegetation. The root formation is fibrous and flowers are white or pale bluish lilac [2]. It is an aggressive competitor that occupies different types of lands where it forms dense strands that prevent the establishment of other flora. It is a menace in plantations and other ecosystems. It suppresses young plantations, crops and smothers vegetation as it possesses allelopathic

Corresponding author: Email: adedayotologbonse@uniuyo.edu.ng : +2348037801881

potentialities and growth inhibitors [3, 4, 5]. The economic value of *C. odorata* is low. Consequently, there is relative paucity of research works on it. In recent decades, it has become a serious weed in the humid tropics of Southeast Asia, Africa and Pacific Islands. Following its introduction to Nigeria, the weed quickly spread through eastern Nigeria in the 1940s and was first reported by Ivens in 1974 to the west of the River Niger in 1955 and from Lagos and its environs in 1960, from where it might have spread into Benin Republic and other West African countries. By 1960, *C. odorata* had occupied the south-eastern states of Nigeria, and possibly spread from there into Cameroon [6, 7, 8]. It spreads rapidly in lands used for forestry, pasture and plantation crops such as rubber, coffee, coconut, cocoa and cashew. The plant is poisonous to livestock as it has exceptionally high level of nitrate (5 to 6 times above the toxic level) in the eaves and young shoots; it can result in tissue anoxia when fed to cattle [9]. Despite the negative effects of the plant, it has patronage from practitioners of traditional medicine.

Figure 1. Leave and flowers of *Chromolaena odorata* L **Source:** Field, 2025) [10]

In the southern part of Nigeria, the leaves are used for wound dressing, skin infection and for haemostasis. The fresh leaves of *C. odorata* or the decoction has been used by practitioners of traditional medicine for the treatment of human burns, soft tissue wounds, ulcerated wounds, burn wounds, postnatal wounds and also for the treatment of leech bites, indigestion and skin infection. It is also used for the treatment of various ailments, such as amenorrhea, catarrh, cold-associated nasal congestion, diabetes, diarrhoea, fever, pertussis and rheumatism, and as a vermifuge [11]. Other pharmacological properties of this plant include anthelminthic [12], antimalarial, analgesic [13,14], anti-inflammatory, antipyretic, antispasmodic [15-17], antimycobacterial, insecticidal, antioxidant, anti-gonorrheal, fungicidal, diuretic [18,19], blood coagulating, and antimicrobial effects [20]. The medicinal values of plants lie in their component phytochemicals such as alkaloids, tannins, flavonoids and other phenolic compounds, which produce a definite physiological action on the human body. Despite the widespread use of *C. odorata*, its impact on the ileum smooth muscle remains poorly understood. While some studies explore the plant's anti-ulcer properties, a focused examination of its effect on the ileum is currently lacking. Given the increasing use of traditional medicine in the health sector, research is needed to determine whether *C. odorata* extracts have any direct effects on the contractility, relaxation and histology of the jejunum smooth muscle, especially as it is often taken via the oral route when used as a herbal mixture for treatments. Phenols have been reported as one of the essential constituents in *C. odorata*. The structure contains a hydroxyl group, a property that is responsible for the scavenging effect of this plant [21].

Nigerian Journal of Pharmaceutical and Applied Science Research,
Vol.14 (4): 35-44; December 2025 ISSN: 2971-737X (Print); ISSN: 2971-7388.
Available at www.nijophasr.net https://doi.org/10.60787/nijophasr-v14-i4-637



Figure 2: Chemical structure of p-coumaric acid and p-hydroxybenzoic acid from C.odorata leaves. Source: Pisutthanan (2006) [21].

This study aimed at evaluating the effect of the methanol extract *Chromolaena odorata* on the jejunum smooth muscle mechanical activities and histology in Wistar rats' model.

2. MATERIALS AND METHOD

2.1 Materials

2.1.1 Biological materials

Fresh leaves of *Chromolaena odorata* were collected from Ekebedi Oboro, Ikwuano LGA, Abia State, Nigeria. The plant was identified and authenticated by a taxonomist of the Department of Botany and Ecological studies, University of Uyo, Uyo, Nigeria, and deposited in the Faculty of Pharmacy Herbarium with a specimen No. UUPH No.10 (c). Thirty (30) healthy albino mice weighing 20g to 30g and twenty (20) Wistar rats were obtained from University of Uyo animal house, and the animals were allowed to acclimatize in the laboratory for a period of seven days. They were allowed free access to feed and water *ad libitum* throughout the period of the experiment. The mice and rats were kept in wooden cages furnished with hardwood chip bedding at ambient temperatures of 28° Celsius.

2.1.2 Chemicals and reagents

water, 10% buffered formalin, ketamine, Atropine, tween 80 (polysorbate 80), 10% formalin and other chemicals. All drugs and chemicals were of standard analytical grades and were purchased from the Pharmacy store of the University Uyo Teaching Hospital, Uyo and a few other chemicals gotten from the Laboratory of the Department of Pharmacology and Toxicology, University of Uyo, Uyo, Nigeria.

2.1.3 Equipment

Aluminum foil, cotton wool, syringes (5ml), cannula, masking tapes, disposable hand gloves and nose mask, breakable plates, beakers (250ml,1000ml), surgical scissors, organ bottles, plain bottles, Organ bath/ kymograph drum, Electronic weighing balance, triple beam balance, stirring rods, pot, Whatman No. 1 filter paper.

2.2 Methods

2.2.1 Preparation of Drugs and extraction

Fresh leaves of *Chromolaena odorata* were carefully separated from the stalks, were washed to remove sand and debris under a running water tap and rinsed with distilled water. The fresh leaves were shade-dried for a period of two weeks. The dried leaves were chopped into pieces and progressively turned into powder, with the use of an electric grinding machine. The resulting powder (400g) was macerated exhaustively in 1500 ml of 80% methanol for 72 hours, and was filtered through a filter paper (Whatman no.1) to obtain a methanolic crude extract. The extract was concentrated by evaporation to dryness in a rotary evaporator at 40 ^{o}C to yield a dried methanolic extract of 96.2g. The percentage yield was 24.05%. This was appropriately labeled and stored in the refrigerator at - 20^{o}C for further use. The volume of *Chromolaena odorata* extract administered to all the animals in the test group in the *in vivo* experiment using a 23G stainless steel oropharyngeal cannula was calculated.

$$\text{Volume administered (mL)} = \frac{\text{weight of the animal (kg) x required dose (mg/kg)}}{\text{Concentration of test drug (mg/mL)}}$$

2.2.2 Preparation of Atropine and other solutions

An atropine injection of 1mg/ml (ATOCAN INJ.) was used for this experiment. A four (4) fold serial dilution was carried out to produce different concentrations ranging from 10^{-2}M Up to 10^{-5}M atropine.

The following were used to make the solution: sodium chloride (8g/L), potassium chloride (0.2g/L), calcium chloride (0.1g/L), sodium dihydrogen phosphate (0.05g/L), magnesium chloride (0.1g/L), glucose(2g/L). These salts were accurately weighed and dissolved in four liters of distilled water.

2.2.3 Experimental / Study Design for acute toxicity study (LD_{50})

Thirty (30) albino mice weighing between 20g to 30g were randomly selected from the animal house unit, Department of Pharmacology and Toxicology and the rats were subdivided into six (6) groups (with n=5 per group). In the first phase of the acute toxicity study using modified Lorke's method, Group I, Group II and Group III mice were administered a single fixed dose of the respective *C. odorata* extract (1000mg dissolved in 10 mL of distilled water) tested in a stepwise procedure (1000, 3000, and 5000 mg/kg body weight of mice). The animals were observed for any sign of toxicity such as rising fur, draping, tremors, excitability, twitching, salivation and mortality for the first 4 hours after the treatment period up to 24 hours. The 1000 mg/kg body weight of the *C. odorata* extract was the highest dose determined not to induce acute toxicity in mice during the first phase of the present study. The second phase was carried out with Group IV, Group V and Group VI mice (n=3 mice per group) by administering a single fixed dose of the *C. odorata* extract tested in a stepwise procedure, 1500 mg/kg for Group IV, 2000 mg/Kg for Group V and 2500 mg/Kg for Group VI. The animals were observed for any toxic effect such as rising fur, draping, tremors, excitability, twitching, salivation and mortality for period of 72 hours.

2.2.4 Study Design for in vivo studies/treatments

Twenty (20) Albino rats weighing between 180 g to 200 g were randomly selected from the animal house unit, department of pharmacology and toxicology and the rats were subdivided into four (4) groups (with n=5 per group) of control, *Chromolaena odorata* extract (273.86 mg/Kg), *Chromolaena odorata* extract (547.72 mg/Kg), *Chromolaena odorata* extract (821.58 mg/Kg). The rats were divided into four (4) groups (n=5). Group 1, rats were administered distilled water (3ml/kg) only as negative control; group 2 were also administered *Chromolaena odorata* extract (273.86mg/kg) body weight; group 3 were administered *Chromolaena odorata* extract (547.72mg/kg); group 4 were administered *Chromolaena odorata* extract (821.58mg/kg). The period of treatment was twenty eight (28) days. The animals were then sacrificed and the jejunum harvested and obtained respectively. At the end of the 28 days of treatment, the animals were fasted for 24 hours after which, they were euthanized with 1.2 mg/Kg of ketamine as an anesthetic agent then on paralysis, they were sacrificed and the ileum harvested, washed with physiological saline solution to remove blood stains and then fixed into the organ bottle containing 10 % buffered formalin and sent for analysis and histological studies.

2.2.5 Experimental Procedures/ protocols in in vitro Animal Studies

Standard experimental procedures as described by Unekwe in 1990 and modified by Tologbonse, were carried out using an organ bath with a slow moving kymograph [22, 23]. The organ bath was properly washed using distilled water after which it was sufficiently filled with physiological solution (Tyrode's solution). The rats were dissected via a V cut on the midline of the anterior abdominal and the jejunum muscle was gotten at the hypogastric region. The isolated jejunum smooth muscle tissue was picked using sterile forceps; a needle was used to pass a thread through the tissue to form a loop through which the tissue holder was to be inserted. Another needle was used to pass a thread through the tissue and this was tied through the arm of the frontal writing lever. Subsequently, the tissue was aerated to ensure that it was alive for the experiment to be successful. A gum was used to maintain proper balance on both sides of the frontal writing lever. At this point, the tissue holder was placed in the organ bath tube containing the physiological salt solution. The tissue was allowed to stabilize for 30-60 minutes before the investigation commenced; also, the appropriate observations were recorded. Standard experimental protocols were observed, hence, standard protocols were used to carry out the following:

i. Determination of the intrinsic mechanical activity of the isolated jejunum tissue in the presence of Tyrode's solution without the various contractile agents.
ii. Dose-response curves of Acetylcholine using isolated jejunum smooth muscle preparation.
iii. Effect of *Chromolaena odorata* extract on the dose-response curve in step ii above,
iv. Effect of *Chromolaena odorata* extract on the relaxation action of Atropine.

a. Histological study of the effect of *Chromolaena odorata* extract in in-vivo studies using experimental rat models.
b. Ethical standards and procedures were observed, the Faculty of Pharmacy, University of Uyo, ethical committee's clearance was obtained, in line with the Principle of Laboratory Animal care: [24].

2.3 Statistical analysis

Analysis of data was done using SPSS software package employing the one way ANOVA followed by Dunnett post Hoc test with significant differences at P<0.05 and P<0.01 respectively. Results were presented as mean ± standard error of mean (SEM).

3. RESULTS

Results were presented as mean ± standard error of mean (SEM). Analysis of data was done using SPSS software package employing the one-way ANOVA followed by Dunnett post Hoc test with significant differences at P<0.05 and P<0.01 respectively.

The results of this study revealed that the LD_{50} of *C. odorata* methanolic extract was calculated and found to be 2738.61 mg/Kg, which indicates that *C. odorata* methanolic extract has low acute toxicity, as shown in the results below and Table 1 and 2 respectively. Furthermore, the results of *in vitro* study on jejunum contractility and relaxations are listed sequentially in Table 3 and Table 4: Also, the histological findings are also presented in Figure 4 to 6 . They help to provide critical insights into the safety and potential toxicity of *C. odorata* extract on Jejunum tissues at the different treatment doses used. See detailed results below:

Calculation on LD_{50}

Table 1. Phase I (using modified Lorke's method)

Serial Number	Groups	Number of mice treated	Number of mortality	% Mortality
1	Control (Water only)	3	0	0
2	*C. odorata* extract (1000mg/kg)	3	0	0
3	*C. odorata* extract (3000mg/kg)	3	3	100
4	*C. odorata* extract (5000mg/kg)	3	3	100

Table 2: Phase II (using modified Lorke's method)

Serial Number	Groups	Number of mice treated	Number of mortality	% Mortality
1	*C. odorata* extract (1500mg/kg)	1	0	0
2	*C. odorata* extract (2000mg/kg)	1	0	0
3	*C. odorata* extract (2500mg/kg)	1	0	0

$LD_{50} = \sqrt{AB}$

$= \sqrt{2500\ x 3000}$

$= \sqrt{7{,}500{,}000}$

LD_{50} = 2,738.61mg/Kg (Lorke's Method).

In the *in vitro* studies- *C. odorata* extract (2×10^{-2} mg/ml, -log [M] = 1.7) induced the maximum relaxation response (-6.0 ± 0.58 mm, 100% of maximum response) as seen in Table 3:

Table 3: Effect of *C. odorata* methanolic extract treatments on jejunum smooth muscle / Atropine

Treatment	Final bath concentration (mg/ml)	-log(m)	Height of concentration (mm)	% of maximum response
Atropine (**Control**)	0.00004	4.4	-9.3 ± 0.83	-
C. odorata extract	2×10^{-2}	1.7	-6.0 ± 0.58*	100
C. odorata extract	2×10^{-4}	3.7	-3.1 ± 0.10*	48.6
C. odorata extract	2×10^{-5}	4.7	-2.2 ± 0.17*	35.3
C. odorata extract	2×10^{-6}	5.7	-1.2 ± 0.17*	20.8

*Values are Mean ± SEM. *The Mean difference is significant at *P<0.05. The low SEM values (0.17–0.58) suggest high precision and reproducibility in the measurements. Dunnett t-tests treat Atropine (0.00004) as control and compare all other groups against it.*

Table 4: Atropine effect on induced extract mechanical activity on jejunum smooth muscle
The cumulative effect of atropine (4×10^{-3} mg/ml, in fixed concentration) on *C. odorata* induced relaxation was assessed:

Final bath concentration (mg/ml)	-log(m)	Height of concentration (mm)	% of maximum response
4×10^{-5}	4.4	-9.3 ± 0.83*	100
4×10^{-5}	4.4	-4.0 ± 0.17	43.7
4×10^{-5}	4.4	-3.0 ± 0.17	33.0
4×10^{-5}	4.4	-2.5 ± 0.17	27..7

*Values are Mean ± SEM, The Mean difference is significant at *P<0.05, The highest concentration (2×10^{-1} mg) elicited the maximum response, while lower concentrations showed progressively reduced relaxation activity. The low SEM values (0.17–0.58) suggest high precision and reproducibility in the measurements. Dunnett t-tests treat Atropine (0.00004) as control and compare all other groups against it.*



Figure 3: Photomicrograph of the longitudinal section of Group 3 (High Dose- 821.58 mg/Kg) treated small intestinal (jejunum) mucosa showing a moderately affected digestive tissue with areas of hyperplasic villi and crypt cells (black arrows), and fibrolysis of the lamina propria (yellow arrow) within the endometrial mucosa. (H&E x100). Inference: Moderately ulcerated.



Figure 4 : Photomicrograph of the longitudinal section of Group 2 (Medium Dose- 547.72 mg/Kg) treated small intestinal (jejunum) mucosa showing a moderately affected digestive tissue with areas of hyperplasic crypt cells (black arrows), and fibrolysis of the lamina propria (yellow arrow) within the endometrial mucosa. (H&E x100). Inference: Moderately ulcerated.

Nigerian Journal of Pharmaceutical and Applied Science Research,
Vol.14 (4): 35-44; December 2025 ISSN: 2971-737X (Print); ISSN: 2971-7388.
Available at www.nijophasr.net https://doi.org/10.60787/nijophasr-v14-i4-637



Figure 5: Photomicrograph of the longitudinal section of Group 1 (Low Dose- 273.86 mg/Kg) treated small intestinal (jejunum) mucosa showing a normal digestive tissue with projecting villi having goblet cells and the crypts of leiberkuhn, laminar propria, presence of glandular cells, and an underlying submucosa. (H&E x100). Inference: Not ulcerated.



Figure 6: Photomicrograph of the Group 4 Control treated with 10 mg/Kg of Distilled water: a control small intestinal (jejunum) mucosa showing a normal digestive tissue with projecting villi (V) having goblet cells (Gc) and epithelial lining cells (Ec), the crypts of leiberkuhn (Cr), laminar propria (Lp), and an underlying submucosa (Sm). (H&E x100). Inference: Not ulcerated.

4. DISCUSSION

The LD_{50} of 2738.61 mg/kg indicates that *C. odorata* methanolic extract has low acute toxicity, as it is well above the threshold for substances considered highly toxic (<50 mg/kg). This finding supports the traditional use of *C. odorata* in herbal medicine, as it suggests a wide therapeutic window. However, the 100% mortality at 3000 mg/kg and 5000 mg/kg in Phase I highlights the need for careful dose selection in therapeutic applications to avoid toxicity. The *in vitro* study evaluated the effect of *C. odorata* methanolic extract on isolated jejunum smooth muscle, with atropine (0.00004 mg/ml, -log[M] = 4.4) as the control. Atropine, a muscarinic receptor antagonist, is known to inhibit acetylcholine-induced contractions, leading to smooth muscle relaxation [24]. *C. odorata* extract induced the maximum relaxation response which was less potent than atropine, this effect was not significant ($P<0.05$) when compared to atropine. Previous studies have identified these phytochemicals as key contributors to the plant's antioxidant, anti-inflammatory, and antispasmodic properties [25]. The relaxation effect may be attributed to the phytochemical constituents of *C. odorata*, particularly flavonoids and phenolic compounds, which are known to modulate smooth muscle activity. Flavonoids, such as quercetin and kaempferol derivatives, have been reported to inhibit calcium influx or interact with G-protein-coupled

receptors, thereby reducing smooth muscle contractility. The mechanism of action may involve inhibition of L-type calcium channels or enhancement of cyclic guanosine monophosphate (cGMP) pathways, similar to nitric oxide-mediated smooth muscle relaxation [26]. The dose-dependent inhibitory response suggests concentration-dependent interaction with these pathways, with higher concentrations saturating the relevant receptors or ion channels. When combined with atropine, a muscarinic receptor antagonist known to induce smooth muscle relaxation, *C. odorata* extract showed a synergistic effect. This suggests that *C. odorata* may enhance atropine's antispasmodic effects, possibly through complementary mechanisms, such as inhibition of muscarinic receptor-mediated contractions or modulation of intracellular calcium levels. When atropine was applied to pre-relaxed jejunum tissues by *C. odorata* extract, there was further relaxation, suggesting a synergistic or additive inhibitory effect. Lower responses in subsequent trials (-4.0 mm, -3.0 mm, -2.5 mm) imply possible receptor desensitization or saturation. These findings aligned with previous studies reporting antispasmodic properties of *C. odorata* [27], supporting its potential use in treating gastrointestinal disorders characterized by spasms, such as irritable bowel syndrome. The histological findings provide critical insights into the safety and potential toxicity of *C. odorata* extract on jejunum tissue. The control group (treated with distilled water) and the low-dose group (273.86 mg/kg) exhibited normal histological features, including intact villi, goblet cells, crypts of Lieberkuhn, and lamina propria, with no signs of ulceration (Figures 5 and 6). These findings indicate that low doses of *C. odorata* extract are safe and do not induce structural damage to the jejunum mucosa. In contrast, the medium-dose (547.72 mg/kg) and high-dose (821.58 mg/kg) groups showed moderate ulceration, characterized by hyperplastic villi and crypt cells and proliferating fibrolysis in the lamina propria (Figures 3 and 4). These changes suggest that higher doses of the extract may induce mucosal irritation or damage, potentially due to cytotoxic compounds such as alkaloids or high nitrate levels [9]. The hyperplasia of crypt cells indicates an adaptive response to mucosal injury; However, the absence of severe ulceration or necrosis indicates that the damage is moderate and potentially reversible. The histological findings correlate with the acute toxicity results, where higher doses (3000 mg/kg and above) caused significant toxicity. The moderate ulceration observed at 547.72 mg/kg and 821.58 mg/kg suggests a dose-dependent toxic effect on the gastrointestinal mucosa, which may limit the therapeutic use of *C. odorata* at higher doses. The presence of bioactive compounds, such as phenolic acids and flavonoids, may contribute to both the therapeutic and toxic effects, as these compounds can have dual roles depending on concentration [28].

5. CONCLUSION

The findings from this study suggest that *C. odorata* exhibits a dose-dependent antispasmodic effect on jejunum smooth muscle, which seems to be mediated mainly through muscarinic receptors, as demonstrated by atropine's antagonistic effects. These results may also give support to the safety profile of *C. odorata* for traditional medicinal uses, especially at low to moderate doses: indicating a need for careful dose optimization. It is strongly recommended that further research work should be carried out on chronic toxicological effects of *C. odorata* for a period of ninety (90) days; also, the detailed mechanisms of its action on other smooth muscle issues should be investigated.

DECLARATIONS

Acknowledgements

We sincerely acknowledge Mr. Nsikan U. Malachy and all the Technical Laboratory Staff of the Department of Pharmacology and Toxicology, University of Uyo, Uyo, Nigeria, for their assistance and technical guidance.

Conflicts of interest

The Authors express no conflicts of interest in this research work among the team.

Authors contributions

Authors 1,7,8 are the primary investigators, while authors 3 and 4 are co-investigators, author 2 and 6 are the main supervisor and co-supervisor respectively; authors 9 and 10 provided the needed technical assistance, finally authors 5,11 and 12 assisted in data analysis and interpretation of results.

Ethical approvals

Ethical Approval Ethical standard and procedures were observed, the Faculty of Pharmacy, University of Uyo ethical committee's clearance was obtained, in line with the Principle of Laboratory Animal care:[24]

6. REFERENCES

[1] Fadyen MC.,2004. Chromolaena odorata (L.) King and Robinson (Asteraceae). In Plant Protection Compendium. Species Profile, CABI Publishing, Wallingford, UK.

[2] Cruttwell RE. The ecology and control of *Chromolaena odorata*. In: Muniappan R (Ed.). *Proceedings of the Third International Workshop on Biological Control and Management of Chromolaena odorata*. Agricultural Experiment Station, University of Guam; 1996:1–9.

[3] Ambika SR, Jayachandra. Allelopathic potential of *Chromolaena odorata* (L.) R.M. King and H. Rob. *Curr Sci.* 1980;49(23):886–888.

[4] Ambika SR, Jayachandra. Allelopathic effects of *Chromolaena odorata* on subsequent crops. *Indian J Weed Sci.* 1982;14(2):94–98.

[5] Muniappan R, Marutani M.1988. *Chromolaena odorata* and its allelopathic potentialities and growth inhibitory properties.Comference Proceedings of the first international workshop on Biological Control of *Chromolaena odorata ,* Agricultural Experiment station. University of Guam, 52 - 60. .

[6] Ivens GW. The problem of *Chromolaena odorata* in Nigeria. *PANS Pest Artic News Summ.* 1974;20(2):140–143.

[7] Odukwe DO. *Chromatolaena odorata* in Nigeria. *Niger Agric J.* 1965;2(1):10–12.

[8] Hoevers R, M'boob SS, 1996. The spread of *Chromolaena odorata* in eastern Nigeria and the African sub-regions. *Weed Sci Bull.* 5;5:25.

[9] Sajise PE, Palad MB, Lales PN. Nitrate toxicity in livestock due to *Chromolaena odorata*. *Philipp Weed Sci Bull.* 1974;1(1):12–16.

[10] Tologbonse AA, Armstrong CU, Omeluko NM, and Ejike IA, 2025.Subchronic Toxicological evaluation of the Leave and flower of *Chromolaena odorata* L. M.Sc. Dissertation research work, Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Uyo, Uyo; 2025.

[11] Goodall JM, Erasmus DJ. Review of the status and integrated control of the invasive alien weed *Chromolaena odorata* in South Africa. *Agric Ecosyst Environ.* 1996;56(3):151–164.

[12] Patel JJ, Acharya SR, Acharya NS. Anthelmintic activity of *Chromolaena odorata* (L.) King and Robinson. *Int J Pharma Sci Res.* 2010;1(3):171–174.

[13] Ongkana T, 2003. Antimalarial and other Pharmacological properties of *Chromolaena odorata* (L.). M.Sc. Thesis , Faculty of Pharmaceutical Sciences, Mahidol University, Bangkok, Thailand . .

[14] Chakraborty AK, Rambhade S, Patil UK. *Chromolaena odorata* (L.): An overview. *J Pharm Res.* 2011;4(3):573–576.

[15] Oludare BE, Tijani AA, Oyeniran OI. Pharmacological properties of *Chromolaena odorata*. *Afr J Med Med Sci.* 2000;29(3–4):233–237.

[16] Phan TT, Hughes MA, Cherry GW. Effects of *Chromolaena odorata* extract on cultured human keratinocytes and fibroblasts. *J Wound Care.* 2001;10(1):504–510.

[17] Caceres A, Menendez H, Mendez E, Cohobon E, Samayoa BE, Jauregui E, Peralta E, Carrillo G. Antigonorrhoeal activity of plants used in Guatemala for the treatment of sexually transmitted diseases. *J Ethnopharmacol.* 1995;48(2):85–88.

[18] Gopinath SM, Suneetha TB, Naik DR. Diuretic activity of *Chromolaena odorata* (L.) R.M. King and H. Robinson. *Pharmacologyonline.* 2009;3:345–350.

[19] Triaratana T, Suwannawong S, Na-Bangchang K. 1991. Blood coagulating effects of *Chromolaena odorata*. *J Med Assoc Thail.*;74(4):216–220.

[20] Borges A, Ferreira C, Saavedra M.J. And Simoes, M 2016.Anti-bacterial activity and mode of action of *Chromolaena odorata* leaf extracts. *Journal of Ethnopharmacology,*192, 236-245.

[21] Pisutthanan N, Liawruangrath S, Bremner JB. Chemical constituents of *Chromolaena odorata*. *Nat Prod Res.* 2006;20(7):636–640.

[22] Unekwe PC, Ogama JO, Chilaka KC, Okonkwo JC, Nwajie EE. Effect of mefloquine on the mechanical activity of mouse isolated rectum and rat urinary bladder strip. *Niger J Physiol Sci.* 19;6(2):109–113.

[23] Tologbonse AA, Unekwe PC, Mbagwu HOC, Essien GE, Bello TE 2018. Effects of artemisinin/artesunate on isolated ileum smooth muscle in animal models. In: *Abstracts of International Conference Proceedings of the West African Society of Toxicology (WASOT)*, UNIABUJA;:65.

[24] National Institutes of Health (NIH). *Principles of Laboratory Animal Care*. NIH Publication No. 85-123; 1996.

[25] Omokhua GE, Onwubiko OC, Asekun OT. Phytochemical and pharmacological studies on *Chromolaena odorata*. *J Med Plants Res.* 2016;10(15):186–194.

[26] Jackson WF. Ion channels and smooth muscle contraction. *Physiol Rev.* 2018;98(1):77–121.

[27] Kouamé PB, Jacques C, Bed G, Silvestre V, Loquet D, Barillé-Nion S. Isolation and characterization of three new compounds from *Chromolaena odorata* with cytotoxic and anticancer properties. *Phytochem Lett.* 2013;6(4):559–563.